Charles Schwab’s Marker Therapeutics MRKR Stock Holding History

Charles Schwab’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,656	Closed	-$26K	–	3609
2021 Q4	$26K	Hold	2,656	–	–	﹤0.01%	3568
2021 Q3	$45K	Hold	2,656	–	–	﹤0.01%	3464
2021 Q2	$75K	Sell	2,656 -4,715	-64%	-$124K	﹤0.01%	3318
2021 Q1	$166K	Hold	7,371	–	–	﹤0.01%	3339
2020 Q4	$107K	Hold	7,371	–	–	﹤0.01%	3319
2020 Q3	$111K	Hold	7,371	–	–	﹤0.01%	3245
2020 Q2	$153K	Buy	7,371 +912	+14%	+$19.9K	﹤0.01%	3204
2020 Q1	$123K	Hold	6,459	–	–	﹤0.01%	3089
2019 Q4	$187K	Hold	6,459	–	–	﹤0.01%	3046
2019 Q3	$331K	Hold	6,459	–	–	﹤0.01%	2947
2019 Q2	$512K	Buy	+6,459	New	+$384K	﹤0.01%	2799

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Charles Schwab's MRKR Position: Q1 2022 in Review

Charles Schwab sold out of Marker Therapeutics (MRKR) in Q1 2022, closing a stake of 2,656 shares — an estimated $26K sold.

Charles Schwab first reported a position in MRKR in Q2 2019 and held it in 11 quarters. The position peaked at $512K in Q2 2019. 49 funds tracked by Wall St. Rank hold MRKR as of Q1 2022.

Charles Schwab reported no remaining Marker Therapeutics position as of Q1 2022 after selling out during the quarter.
Charles Schwab sold 2,656 Marker Therapeutics shares in Q1 2022, an estimated $26K.
Charles Schwab first reported a position in Marker Therapeutics in Q2 2019 and held it in 11 quarters.
Charles Schwab's Marker Therapeutics position peaked at $512K in Q2 2019.
49 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.